Kiniksa Pharmaceuticals, Ltd. Expected to Earn FY2021 Earnings of ($2.25) Per Share (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Equities researchers at Wedbush boosted their FY2021 earnings per share estimates for Kiniksa Pharmaceuticals in a research note issued to investors on Monday, January 10th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($2.25) for the year, up from their previous estimate of ($2.26). Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q4 2021 earnings at ($0.47) EPS, Q1 2022 earnings at ($0.45) EPS, Q2 2022 earnings at ($0.37) EPS, Q3 2022 earnings at ($0.34) EPS, Q4 2022 earnings at ($0.32) EPS, FY2022 earnings at ($1.48) EPS, FY2023 earnings at ($0.98) EPS and FY2024 earnings at ($0.36) EPS.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Monday, November 1st. The company reported ($0.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.21. The company had revenue of $12.10 million during the quarter, compared to analyst estimates of $9.92 million.

A number of other analysts also recently issued reports on KNSA. Zacks Investment Research raised shares of Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a report on Wednesday, November 3rd. Bank of America cut their price objective on shares of Kiniksa Pharmaceuticals from $37.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday, December 29th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Tuesday, November 2nd.

Shares of KNSA opened at $11.33 on Thursday. Kiniksa Pharmaceuticals has a 52 week low of $10.30 and a 52 week high of $24.70. The firm has a market cap of $780.50 million, a P/E ratio of -4.43 and a beta of -0.09. The firm’s 50-day simple moving average is $12.43 and its 200 day simple moving average is $12.78.

Several institutional investors have recently modified their holdings of KNSA. Macquarie Group Ltd. lifted its holdings in shares of Kiniksa Pharmaceuticals by 1,207.2% during the 3rd quarter. Macquarie Group Ltd. now owns 4,353 shares of the company’s stock worth $50,000 after acquiring an additional 4,020 shares during the period. BNP Paribas Arbitrage SA lifted its holdings in shares of Kiniksa Pharmaceuticals by 424.5% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 5,633 shares of the company’s stock worth $64,000 after acquiring an additional 4,559 shares during the period. Hsbc Holdings PLC acquired a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $115,000. Invesco Ltd. increased its position in Kiniksa Pharmaceuticals by 15.9% during the 3rd quarter. Invesco Ltd. now owns 12,736 shares of the company’s stock worth $145,000 after purchasing an additional 1,751 shares in the last quarter. Finally, Man Group plc acquired a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $175,000. 42.86% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404.

Read More: Quick Ratio

Earnings History and Estimates for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.